Pharma & Healthcare

Global ALK Inhibitors Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global ALK Inhibitors market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Pfizer
Novartis
Roche
Takeda Pharmaceuticals
Betta Pharmaceuticals
Qilu Pharmaceutical
Wanbang Biopharmaceuticals
Jiangsu Aosaikang Pharmaceutical
Natco Pharma
Segment by Type
Crizotinib
Ceritinib
Ensartinib
Alectinib
Brigatinib
Lorlatinib
Iruplinalkib
Other
Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the ALK Inhibitors study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to ALK Inhibitors: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global ALK Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Ensartinib
1.2.5 Alectinib
1.2.6 Brigatinib
1.2.7 Lorlatinib
1.2.8 Iruplinalkib
1.2.9 Other
1.3 Market Segmentation by Application
1.3.1 Global ALK Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global ALK Inhibitors Revenue Estimates and Forecasts 2020-2031
2.2 Global ALK Inhibitors Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global ALK Inhibitors Sales Estimates and Forecasts 2020-2031
2.4 Global ALK Inhibitors Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global ALK Inhibitors Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global ALK Inhibitors Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Crizotinib Market Size by Manufacturers
3.5.2 Ceritinib Market Size by Manufacturers
3.5.3 Ensartinib Market Size by Manufacturers
3.5.4 Alectinib Market Size by Manufacturers
3.5.5 Brigatinib Market Size by Manufacturers
3.5.6 Lorlatinib Market Size by Manufacturers
3.5.7 Iruplinalkib Market Size by Manufacturers
3.5.8 Other Market Size by Manufacturers
3.6 Global ALK Inhibitors Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global ALK Inhibitors Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global ALK Inhibitors Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global ALK Inhibitors Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global ALK Inhibitors Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America ALK Inhibitors Sales and Revenue by Type (2020-2031)
6.4 North America ALK Inhibitors Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America ALK Inhibitors Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe ALK Inhibitors Sales and Revenue by Type (2020-2031)
7.4 Europe ALK Inhibitors Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe ALK Inhibitors Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific ALK Inhibitors Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific ALK Inhibitors Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific ALK Inhibitors Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America ALK Inhibitors Sales and Revenue by Type (2020-2031)
9.4 Central and South America ALK Inhibitors Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America ALK Inhibitors Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa ALK Inhibitors Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa ALK Inhibitors Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa ALK Inhibitors Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview
11.1.3 Pfizer ALK Inhibitors Product Models, Descriptions and Specifications
11.1.4 Pfizer ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Pfizer ALK Inhibitors Sales by Product in 2024
11.1.6 Pfizer ALK Inhibitors Sales by Application in 2024
11.1.7 Pfizer ALK Inhibitors Sales by Geographic Area in 2024
11.1.8 Pfizer ALK Inhibitors SWOT Analysis
11.1.9 Pfizer Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Business Overview
11.2.3 Novartis ALK Inhibitors Product Models, Descriptions and Specifications
11.2.4 Novartis ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Novartis ALK Inhibitors Sales by Product in 2024
11.2.6 Novartis ALK Inhibitors Sales by Application in 2024
11.2.7 Novartis ALK Inhibitors Sales by Geographic Area in 2024
11.2.8 Novartis ALK Inhibitors SWOT Analysis
11.2.9 Novartis Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche ALK Inhibitors Product Models, Descriptions and Specifications
11.3.4 Roche ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Roche ALK Inhibitors Sales by Product in 2024
11.3.6 Roche ALK Inhibitors Sales by Application in 2024
11.3.7 Roche ALK Inhibitors Sales by Geographic Area in 2024
11.3.8 Roche ALK Inhibitors SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Takeda Pharmaceuticals
11.4.1 Takeda Pharmaceuticals Corporation Information
11.4.2 Takeda Pharmaceuticals Business Overview
11.4.3 Takeda Pharmaceuticals ALK Inhibitors Product Models, Descriptions and Specifications
11.4.4 Takeda Pharmaceuticals ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Takeda Pharmaceuticals ALK Inhibitors Sales by Product in 2024
11.4.6 Takeda Pharmaceuticals ALK Inhibitors Sales by Application in 2024
11.4.7 Takeda Pharmaceuticals ALK Inhibitors Sales by Geographic Area in 2024
11.4.8 Takeda Pharmaceuticals ALK Inhibitors SWOT Analysis
11.4.9 Takeda Pharmaceuticals Recent Developments
11.5 Betta Pharmaceuticals
11.5.1 Betta Pharmaceuticals Corporation Information
11.5.2 Betta Pharmaceuticals Business Overview
11.5.3 Betta Pharmaceuticals ALK Inhibitors Product Models, Descriptions and Specifications
11.5.4 Betta Pharmaceuticals ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Betta Pharmaceuticals ALK Inhibitors Sales by Product in 2024
11.5.6 Betta Pharmaceuticals ALK Inhibitors Sales by Application in 2024
11.5.7 Betta Pharmaceuticals ALK Inhibitors Sales by Geographic Area in 2024
11.5.8 Betta Pharmaceuticals ALK Inhibitors SWOT Analysis
11.5.9 Betta Pharmaceuticals Recent Developments
11.6 Qilu Pharmaceutical
11.6.1 Qilu Pharmaceutical Corporation Information
11.6.2 Qilu Pharmaceutical Business Overview
11.6.3 Qilu Pharmaceutical ALK Inhibitors Product Models, Descriptions and Specifications
11.6.4 Qilu Pharmaceutical ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Qilu Pharmaceutical Recent Developments
11.7 Wanbang Biopharmaceuticals
11.7.1 Wanbang Biopharmaceuticals Corporation Information
11.7.2 Wanbang Biopharmaceuticals Business Overview
11.7.3 Wanbang Biopharmaceuticals ALK Inhibitors Product Models, Descriptions and Specifications
11.7.4 Wanbang Biopharmaceuticals ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Wanbang Biopharmaceuticals Recent Developments
11.8 Jiangsu Aosaikang Pharmaceutical
11.8.1 Jiangsu Aosaikang Pharmaceutical Corporation Information
11.8.2 Jiangsu Aosaikang Pharmaceutical Business Overview
11.8.3 Jiangsu Aosaikang Pharmaceutical ALK Inhibitors Product Models, Descriptions and Specifications
11.8.4 Jiangsu Aosaikang Pharmaceutical ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
11.9 Natco Pharma
11.9.1 Natco Pharma Corporation Information
11.9.2 Natco Pharma Business Overview
11.9.3 Natco Pharma ALK Inhibitors Product Models, Descriptions and Specifications
11.9.4 Natco Pharma ALK Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Natco Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 ALK Inhibitors Industry Chain
12.2 ALK Inhibitors Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 ALK Inhibitors Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 ALK Inhibitors Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 ALK Inhibitors Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global ALK Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global ALK Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global ALK Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global ALK Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global ALK Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global ALK Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global ALK Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global ALK Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global ALK Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global ALK Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global ALK Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global ALK Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global ALK Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global ALK Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ALK Inhibitors as of 2024)
Table 16. Global ALK Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global ALK Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers ALK Inhibitors Manufacturing Base and Headquarters
Table 19. Global ALK Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global ALK Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global ALK Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global ALK Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global ALK Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global ALK Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global ALK Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global ALK Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. ALK Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global ALK Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global ALK Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global ALK Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America ALK Inhibitors Growth Accelerators and Market Barriers
Table 37. North America ALK Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America ALK Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe ALK Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe ALK Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe ALK Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific ALK Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific ALK Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific ALK Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia ALK Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America ALK Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America ALK Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa ALK Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa ALK Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Pfizer Corporation Information
Table 51. Pfizer Description and Major Businesses
Table 52. Pfizer Product Models, Descriptions and Specifications
Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Pfizer Sales Value Proportion by Product in 2024
Table 55. Pfizer Sales Value Proportion by Application in 2024
Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 57. Pfizer ALK Inhibitors SWOT Analysis
Table 58. Pfizer Recent Developments
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Major Businesses
Table 61. Novartis Product Models, Descriptions and Specifications
Table 62. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Novartis Sales Value Proportion by Product in 2024
Table 64. Novartis Sales Value Proportion by Application in 2024
Table 65. Novartis Sales Value Proportion by Geographic Area in 2024
Table 66. Novartis ALK Inhibitors SWOT Analysis
Table 67. Novartis Recent Developments
Table 68. Roche Corporation Information
Table 69. Roche Description and Major Businesses
Table 70. Roche Product Models, Descriptions and Specifications
Table 71. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Roche Sales Value Proportion by Product in 2024
Table 73. Roche Sales Value Proportion by Application in 2024
Table 74. Roche Sales Value Proportion by Geographic Area in 2024
Table 75. Roche ALK Inhibitors SWOT Analysis
Table 76. Roche Recent Developments
Table 77. Takeda Pharmaceuticals Corporation Information
Table 78. Takeda Pharmaceuticals Description and Major Businesses
Table 79. Takeda Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Takeda Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Takeda Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Takeda Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Takeda Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Takeda Pharmaceuticals ALK Inhibitors SWOT Analysis
Table 85. Takeda Pharmaceuticals Recent Developments
Table 86. Betta Pharmaceuticals Corporation Information
Table 87. Betta Pharmaceuticals Description and Major Businesses
Table 88. Betta Pharmaceuticals Product Models, Descriptions and Specifications
Table 89. Betta Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Betta Pharmaceuticals Sales Value Proportion by Product in 2024
Table 91. Betta Pharmaceuticals Sales Value Proportion by Application in 2024
Table 92. Betta Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 93. Betta Pharmaceuticals ALK Inhibitors SWOT Analysis
Table 94. Betta Pharmaceuticals Recent Developments
Table 95. Qilu Pharmaceutical Corporation Information
Table 96. Qilu Pharmaceutical Description and Major Businesses
Table 97. Qilu Pharmaceutical Product Models, Descriptions and Specifications
Table 98. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Qilu Pharmaceutical Recent Developments
Table 100. Wanbang Biopharmaceuticals Corporation Information
Table 101. Wanbang Biopharmaceuticals Description and Major Businesses
Table 102. Wanbang Biopharmaceuticals Product Models, Descriptions and Specifications
Table 103. Wanbang Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Wanbang Biopharmaceuticals Recent Developments
Table 105. Jiangsu Aosaikang Pharmaceutical Corporation Information
Table 106. Jiangsu Aosaikang Pharmaceutical Description and Major Businesses
Table 107. Jiangsu Aosaikang Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Jiangsu Aosaikang Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Jiangsu Aosaikang Pharmaceutical Recent Developments
Table 110. Natco Pharma Corporation Information
Table 111. Natco Pharma Description and Major Businesses
Table 112. Natco Pharma Product Models, Descriptions and Specifications
Table 113. Natco Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Natco Pharma Recent Developments
Table 115. Key Raw Materials Distribution
Table 116. Raw Materials Key Suppliers
Table 117. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 118. Milestones in Production Technology Evolution
Table 119. Distributors List
Table 120. Market Trends and Market Evolution
Table 121. Market Drivers and Opportunities
Table 122. Market Challenges, Risks, and Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources


List of Figures
Figure 1. ALK Inhibitors Product Picture
Figure 2. Global ALK Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Crizotinib Product Picture
Figure 4. Ceritinib Product Picture
Figure 5. Ensartinib Product Picture
Figure 6. Alectinib Product Picture
Figure 7. Brigatinib Product Picture
Figure 8. Lorlatinib Product Picture
Figure 9. Iruplinalkib Product Picture
Figure 10. Other Product Picture
Figure 11. Global ALK Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Hospital and Clinic
Figure 13. Retail Pharmacies
Figure 14. Other
Figure 15. ALK Inhibitors Report Years Considered
Figure 16. Global ALK Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 18. Global ALK Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 19. Global ALK Inhibitors Revenue Market Share by Region (2020-2031)
Figure 20. Global ALK Inhibitors Sales (2020-2031) & (K Units)
Figure 21. Global ALK Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 22. Global ALK Inhibitors Sales Market Share by Region (2020-2031)
Figure 23. Top 5 and Top 10 Manufacturers ALK Inhibitors Sales Volume Market Share in 2024
Figure 24. Global ALK Inhibitors Revenue Market Share Ranking (2024)
Figure 25. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 26. Crizotinib Revenue Market Share by Manufacturer in 2024
Figure 27. Ceritinib Revenue Market Share by Manufacturer in 2024
Figure 28. Ensartinib Revenue Market Share by Manufacturer in 2024
Figure 29. Alectinib Revenue Market Share by Manufacturer in 2024
Figure 30. Brigatinib Revenue Market Share by Manufacturer in 2024
Figure 31. Lorlatinib Revenue Market Share by Manufacturer in 2024
Figure 32. Iruplinalkib Revenue Market Share by Manufacturer in 2024
Figure 33. Other Revenue Market Share by Manufacturer in 2024
Figure 34. Global ALK Inhibitors Sales Market Share by Type (2020-2031)
Figure 35. Global ALK Inhibitors Revenue Market Share by Type (2020-2031)
Figure 36. Global ALK Inhibitors Sales Market Share by Application (2020-2031)
Figure 37. Global ALK Inhibitors Revenue Market Share by Application (2020-2031)
Figure 38. North America ALK Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 39. North America ALK Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 40. North America Top 5 Manufacturers ALK Inhibitors Sales Revenue (US$ Million) in 2024
Figure 41. North America ALK Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 42. North America ALK Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 43. North America ALK Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 44. North America ALK Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. US ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 46. Canada ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 47. Mexico ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 48. Europe ALK Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 49. Europe ALK Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Europe Top 5 Manufacturers ALK Inhibitors Sales Revenue (US$ Million) in 2024
Figure 51. Europe ALK Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 52. Europe ALK Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 53. Europe ALK Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 54. Europe ALK Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Germany ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 56. France ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 57. U.K. ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 58. Italy ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 59. Russia ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 60. Asia-Pacific ALK Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 61. Asia-Pacific ALK Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Asia-Pacific Top 8 Manufacturers ALK Inhibitors Sales Revenue (US$ Million) in 2024
Figure 63. Asia-Pacific ALK Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 64. Asia-Pacific ALK Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 65. Asia-Pacific ALK Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 66. Asia-Pacific ALK Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Indonesia ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 68. Japan ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 69. South Korea ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 70. China Taiwan ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 71. India ALK Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 72. Central and South America ALK Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 73. Central and South America ALK Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Central and South America Top 5 Manufacturers ALK Inhibitors Sales Revenue (US$ Million) in 2024
Figure 75. Central and South America ALK Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 76. Central and South America ALK Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Central and South America ALK Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 78. Central and South America ALK Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. Brazil ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 80. Argentina ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 81. Middle East, and Africa ALK Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 82. Middle East and Africa ALK Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 83. Middle East and Africa Top 5 Manufacturers ALK Inhibitors Sales Revenue (US$ Million) in 2024
Figure 84. Middle East and Africa ALK Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 85. South America ALK Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 86. Middle East and Africa ALK Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 87. Middle East and Africa ALK Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 88. GCC Countries ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 89. Turkey ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 90. Egypt ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 91. South Africa ALK Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 92. ALK Inhibitors Industry Chain Mapping
Figure 93. Regional ALK Inhibitors Manufacturing Base Distribution (%)
Figure 94. Global ALK Inhibitors Production Market Share by Region (2020-2031)
Figure 95. ALK Inhibitors Production Process
Figure 96. Regional ALK Inhibitors Production Cost Structure
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies